新型雄激素剥夺疗法（ADT）治疗晚期前列腺癌
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.
作者信息
Aragon-Ching Jeanny B, Dahut William L
机构信息
Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.
出版信息
Drug Discov Today Ther Strateg. 2010 Jul 1;7(1-2):31-35. doi: 10.1016/j.ddstr.2011.02.004.
Abstract
Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer.
摘要
雄激素剥夺疗法一直是晚期和转移性前列腺癌的主要治疗方法。使用靶向雄激素受体及其信号通路的新型药物提供了一种既安全又有效的有前景的方法。我们描述了这些化合物在临床开发中使用的基本原理，以及在转移性前列腺癌不断变化的治疗模式中如何最好地纳入这些新出现的疗法所面临的现有挑战。
相似文献
1
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.新型雄激素剥夺疗法（ADT）治疗晚期前列腺癌
Drug Discov Today Ther Strateg. 2010 Jul 1;7(1-2):31-35. doi: 10.1016/j.ddstr.2011.02.004.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
Intermittent androgen deprivation therapy in advanced prostate cancer.晚期前列腺癌的间歇性雄激素剥夺疗法
Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2.
4
Targeting the androgen receptor signaling pathway in advanced prostate cancer.针对晚期前列腺癌的雄激素受体信号通路。
Am J Health Syst Pharm. 2022 Jul 22;79(15):1224-1235. doi: 10.1093/ajhp/zxac105.
5
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.雄激素剥夺疗法对晚期前列腺癌患者心血管系统的影响。
Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727.
6
Contemporary role of androgen deprivation therapy for prostate cancer.雄激素剥夺疗法在前列腺癌中的当代作用。
Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19.
7
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.醋酸阿比特龙联合雄激素剥夺疗法对比单独雄激素剥夺疗法用于转移性激素敏感性前列腺癌。
Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2.
8
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.前列腺癌中雄激素剥夺治疗耐药的分子机制。
Oncotarget. 2016 Sep 27;7(39):64447-64470. doi: 10.18632/oncotarget.10901.
9
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.高危转移性去势敏感性前列腺癌患者的临床结局：观察性 J-ROCK 研究的 3 年中期分析。
Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30.
10
Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.多西他赛联合雄激素受体轴靶向治疗和雄激素剥夺治疗在转移性激素敏感前列腺癌中的应用：一项网状荟萃分析。
Eur Urol Oncol. 2022 Oct;5(5):494-502. doi: 10.1016/j.euo.2022.06.003. Epub 2022 Jul 8.
引用本文的文献
1
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.生殖系统癌症中的分子通路：聚焦前列腺癌和卵巢癌
Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5.
2
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.恩杂鲁胺和米非司酮（一种糖皮质激素受体拮抗剂）治疗转移性去势抵抗性前列腺癌的 I/II 期试验。
Clin Cancer Res. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049.
3
Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.α（1,6）岩藻糖基转移酶过表达在去势抵抗性前列腺癌细胞发展中的作用。
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):137-146. doi: 10.1038/s41391-017-0016-7. Epub 2018 Jan 16.
4
Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo.黏菌素对 PC-3 细胞和源自 PC-3 的肿瘤干细胞的体内外抗肿瘤作用。
Biomed Res Int. 2017;2017:4101653. doi: 10.1155/2017/4101653. Epub 2017 Jun 6.
5
Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.E3泛素连接酶对雄激素受体的调控：增减之间
Receptors Clin Investig. 2014;1(5). doi: 10.14800/rci.122.
本文引用的文献
1
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
2
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.MDV3100 在去势抵抗性前列腺癌中的抗肿瘤活性：一项 1-2 期研究。
Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.
3
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.醋酸阿比特龙的 CYP17 抑制剂的 I 期临床试验表明，在接受过酮康唑治疗的去势抵抗性前列腺癌患者中具有临床活性。
J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.
4
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.醋酸阿比特龙抑制 CYP17 可显著持久抑制多西他赛治疗失败后的去势抵抗性前列腺癌。
J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.
5
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.醋酸阿比特龙联合泼尼松治疗多西他赛治疗失败的去势抵抗性前列腺癌的多中心 II 期研究。
J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.
6
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.CYP17阻断的抗肿瘤活性表明，去势抵抗性前列腺癌通常仍由激素驱动。
Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9.
7
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.醋酸阿比特龙对CYP17的选择性抑制在去势抵抗性前列腺癌的治疗中具有高度活性。
J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.
8
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.开发用于治疗晚期前列腺癌的第二代抗雄激素药物。
Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.
9
CYP17 inhibition as a hormonal strategy for prostate cancer.CYP17抑制作为前列腺癌的一种激素治疗策略。
Nat Clin Pract Urol. 2008 Nov;5(11):610-20. doi: 10.1038/ncpuro1237.
10
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.雄激素受体失活有助于17α-羟化酶/17,20-裂解酶抑制剂3β-羟基-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯在前列腺癌中的抗肿瘤疗效。
Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230.
Zotero 插件